# QantX

> QantX is a VC fund in Exeter backing Health Care and Medical. See 27 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Exeter, United Kingdom
- Total investments: 27
- Last investment: Jul 2026
- Lead investor: 22%
- Last updated: Aug 2026
- Website: https://www.qantx.co.uk

QantX is a VC fund in Exeter focused on Health Care and Medical. High impact innovation investment

## Contacts

5 contacts available for QantX. Shizune tracks 1 team members at QantX. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/qantx?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $471k–$6.5M |
| Angel | $382k–$1.3M |
| Pre-Seed | $764k–$1.1M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 22% |
| Medical | 4 | 15% |
| Biotechnology | 3 | 11% |
| Pharmaceutical | 3 | 11% |
| SaaS | 2 | 7% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 11 | 41% |
| Angel | 3 | 11% |
| Pre-Seed | 3 | 11% |
| Funding Round | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Richard Haycock | CEO | 9 | https://shizune.co/investors/profile/richard-haycock-6928 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Revolver Therapeutics | Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K | Pre-Seed | Jul 03, 2026 |  |
| Neuronostics | Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP. | $4M | Seed | Jun 30, 2026 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $3.9M | Seed | May 27, 2026 |  |
| LabCycle | LabCycle is the world's first company to recycle hazardous plastic waste from laboratories (service) as well as the first to create 100% recycled laboratory consumables (product). Working with public and private labs, we are driving the circular economy of lab plastics to reduce the 5.5m tonnes of lab waste annually. A few highlights of ourprogress to date: • Proven impact - saving 90% of CO2 emissions & 93% energy compared to current alternatives: incineration and autoclave (LCA available upon request).• Technological validation creating the world's first 100% circular lab consumables including petri dishes, test tubes and more.• Secured commercial contracts with the NHS, several private companies and also universities. We are raising £1.5m to scale our patent pending technology to serve our growing demand after over 150+ organic expressions of interests following our feature in BBC news. The funding will establish the first automated decontamination system of our network, recycling over 350 tonnes annually, saving over 1000+ tonnes of carbon. | $1.3M | Seed | Jan 19, 2026 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M | Seed | Aug 28, 2025 |  |
| Lutra Health | Lutra Health mission is to connect eyecare providers and equip them with the tools they need to deliver care more efficiently and effectively. | $471K | Seed | Jun 20, 2025 |  |
| Light Trace Photonics | Light Trace Photonics utilizes the power of integrated photonics to provide a variety of products and services that aid in educational and innovative endeavors. | $759.3K | Seed | Nov 20, 2024 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M | Seed | Nov 04, 2024 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M | Seed | Nov 04, 2024 |  |
| Kelpi | Kelpi is a sustainable biotech start-up bio-refining seaweed to make bioplastic packaging that is marine-safe and home-compostable. | $5.5M | Seed | May 30, 2024 |  |

10 of 27 investments shown.

## Co-investors
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-2) — VC Fund, 7 deals together
- [Meridian Health Ventures](https://shizune.co/investors/profile/khp-ventures) — VC Fund, 6 deals together
- [Emerging Longevity Ventures](https://shizune.co/investors/profile/emerging-longevity-ventures) — VC Fund, 5 deals together
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 5 deals together
- [Lifespan Vision Ventures](https://shizune.co/investors/profile/lifespan-vision-ventures) — VC Fund, 5 deals together
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Medical Investors in United Kingdom](https://shizune.co/investors/medical-investors-united-kingdom)
- [Medical VC Funds in United Kingdom](https://shizune.co/investors/medical-vc-funds-united-kingdom)

## FAQ

### What does QantX invest in?

QantX invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Angel stage. Most of the 27 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is QantX's check size?

QantX typically joins rounds of $471k–$6.5M at Seed, $382k–$1.3M at Angel and $764k–$1.1M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds QantX participates in.

### How do I contact QantX?

Public channels for QantX include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at QantX?

The team at QantX includes Richard Haycock (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co